Filing Information

Inventor(s)	Jonathan S. Stamler ·
Assignee(s)	Duke University ·  View assignee updates
Attorney/Agent(s)	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. · Ivor R. Elrifi · Matthew Pavao ·
Primary Examiner	John Pak ·
Application Number	US9782077
Filing date	02/14/2001
Issue date	05/16/2006
Prior Publication Data	US20010012834 - 08/09/2001
Predicted expiration date	08/25/2020
Patent term adjustment	352
U.S. Classifications	424/718  · 514/663  · 424/703  · 424/708  · 424/709  · 424/711  · 424/713  · 514/474  · 514/561  · 514/562  · 514/563  · 514/645  · 424/607  · 514/708  · 514/709  · 514/711  · 514/740  · 514/771  · 514/826  · 514/851  · 514/929  · 514/958  · 514/959  · 424/600  ·
International Classifications	A61K31198  · A61K31375  · A61K3300  · A61K4500  · A61K972  · A61P1100  · A61P1106  · A61P900  ·
Kind Code	B2
Related U.S. Application Data	CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of U.S. application Ser. No. 09/390,215, filed on Sep. 8, 1999, now U.S. Pat. No. 6,314,956.

Patent Family

Abstract

Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Independent Claims | See all claims (18)

1. 1. A method for treating a pulmonary disorder associated with depletion of the S-nitrosoglutathione pool in the lung or depletion of the glutathione pool in the lung or production of reactive oxygen species in the lung of a patient having such disorder which comprises delivering into the lungs of said patient as a gas, a therapeutically effective amount of an agent selected from the group consisting of: (a) compounds having an NO group and having a hypoxia relieving and smooth muscle constriction relieving effect with the said NO group being bound in said compound so it does not form NO2, NO, N2O3, N2O4, OONO− and OONO• and any products of their interaction with NO or NO2; and (b) N2O3; and (c) NOX, wherein X is halogen, hydrogen or CN, which causes repletion or increase of the S-nitrosoglutathione pool in the lung or protects against toxicity where glutathione is depleted in the lung or where reactive oxygen species are increased in the lung and does so independently of reaction with oxygen.